IGC Pharma Enrolls ~80% Participants In Its Phase 2 CALMA Clinical Study Of IGC-AD1 For Agitation Associated With Alzheimer's Disease
Benzinga Newsdesk 6 months ago
News
IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's
IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease.